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Abstract Accurate measurement of the marginal health-
care costs associated with different diseases and health
conditions is important, especially for increasingly preva-
lent conditions such as obesity. However, existing obser-
vational study designs cannot identify the causal impact of
disease on healthcare costs. This paper explores the pos-
sibilities for causal inference offered by Mendelian ran-
domization, a form of instrumental variable analysis that
uses genetic variation as a proxy for modifiable risk
exposures, to estimate the effect of health conditions on
cost. Well-conducted genome-wide association studies
provide robust evidence of the associations of genetic
variants with health conditions or disease risk factors. The
subsequent causal effects of these health conditions on cost
can be estimated using genetic variants as instruments for
the health conditions. This is because the approximately
random allocation of genotypes at conception means that
many genetic variants are orthogonal to observable and
unobservable confounders. Datasets with linked genotypic
and resource use information obtained from electronic
medical records or from routinely collected administrative
data are now becoming available and will facilitate this
form of analysis. We describe some of the methodological
issues that arise in this type of analysis, which we illustrate
by considering how Mendelian randomization could be
used to estimate the causal impact of obesity, a complex
trait, on healthcare costs. We describe some of the data
sources that could be used for this type of analysis. We
conclude by considering the challenges and opportunities
offered by Mendelian randomization for economic
evaluation.
Key Points for Decision Makers
The causal effects of health conditions on cost can be
estimated using genetic variants as instruments for
health conditions.
This form of analysis—Mendelian randomization—
can identify causal effects because genetic variants
that influence health status may be unrelated to
known and unknown confounders.
Datasets with linked genotypic and resource use
information are now becoming available and will
facilitate this form of analysis.
1 Introduction
Accurate estimates of the marginal medical healthcare
costs that are incurred as a consequence of specific health
conditions are important. Estimates of cost are fundamental
to the economic evaluation of healthcare technologies,
whether undertaken alongside randomized controlled trials
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(RCTs) [1] or as an element of decision-analytic modelling
[2, 3]. Health system sustainability depends on an under-
standing of changes in population health and associated
healthcare costs [4–6].
Neither observational studies nor RCTs offer a wholly
satisfactory means of estimating the impact of different
health conditions on cost. Observational studies can esti-
mate the correlations between healthcare costs and health
conditions but generally cannot identify causal relation-
ships [7]. It is particularly difficult to infer causal effects of
specific conditions on healthcare costs because of prevalent
comorbidities and common causes of health outcomes and
healthcare costs such as socioeconomic status (confound-
ing), complicated natural histories (reverse causality) and
self-reported health status (measurement error).
Many of these problems cannot be resolved in RCTs.
Trials are rarely powered to detect differences in cost-re-
lated outcomes [8]. It may be neither feasible nor ethical to
expose patients to the risks of an intervention solely to
collect information on cost associated with different health
conditions [9]. Patients recruited to RCTs may not be
representative of the populations concerned. Cost data
collected in RCTs may have limited generalizability, may
not relate to the costs that would arise in routine practice,
may be related to intermediate rather than final outcomes
and may not be collected for the full period over which a
health condition affects cost [10].
We describe recent developments in genetic epidemi-
ology that offer a new way of estimating the causal impact
of health conditions on healthcare cost. The methodology
of Mendelian randomization, which uses genetic variants
as instrumental variables, offers a means of addressing the
limitations of existing study designs. In particular, the
ethical and feasibility issues that would prohibit the con-
duct of an RCT are avoided, but some of the advantages of
interventional studies in relation to causal inference are
retained.
We illustrate how robust estimates of causal effects of
health conditions on costs could contribute to economic
evaluation, and health economics more generally, by con-
sidering the relationship between obesity and cost as a
motivating example throughout the paper. Obesity is an
increasingly prevalent condition [11] that is associated with
a range of adverse health [11] and economic [12]
outcomes.
Improved estimates of the causal relation between health
conditions (such as obesity) and healthcare cost could offer
important new evidence to at least three important areas of
health economics. The first area is decision-analytic mod-
elling. Decision-analytic models, which synthesise infor-
mation from a variety of sources, including observational
studies and RCTs, are increasingly recommended as the
most appropriate vehicle for cost-effectiveness analysis
[13]. For example, simulation of the lifetime consequences
of obesity requires information on the cost consequences of
different health states that are defined by body mass index
(BMI). The conclusions of these studies are likely to be
more secure if they are informed by robust causal evidence.
The second area is health system management. For
example, in the absence of accurate information on the cost
consequences of obesity, how should healthcare funders
react to information that indicates the prevalence of obesity
is expected to continue to increase?
The third area relates to targets for intervention. For
example, if an apparent association of BMI with cost is
actually confounded by an association of obesity with
mental health status, then an intervention targeted solely at
reducing adiposity is likely to be neither effective nor cost
effective. Improved knowledge of causal relationships will
help avoid wasteful research effort and facilitate the setting
of research priorities [14].
The objective of this paper is to provide an overview
of the potential role of Mendelian randomization in esti-
mating the causal effect of health conditions on healthcare
cost. We begin by briefly describing the need for
improved methods for causal inference when analysing
observational data, then set out the genetic basis for
Mendelian randomization and its relationship to instru-
mental variables analysis. We describe the key conditions
that must be met for this form of instrumental variable
analysis to produce valid causal estimates of effect, with
particular regard to the specific issues and biological
contexts that arise when analysing genetic variants as
instrumental variables.
To make this concrete, we describe the methodological
issues that would arise when attempting to use Mendelian
randomization to estimate the causal effects of obesity on
healthcare cost. We use this example throughout the paper
to link together the methodological issues. We then con-
sider the data sources that could facilitate this type of
analysis, which would represent a novel use of the large
linked genomic cohort datasets that are now being devel-
oped and made available to researchers.
We conclude by summarising some the challenges and
opportunities offered by Mendelian randomization for the
causal analysis of cost.
2 Genetic Variants and Instrumental Variables
Analysis
2.1 Rationale
The rationale for undertaking causal analysis of the form
described below is that the relationship of some exposure
(such as BMI) to an outcome (such as healthcare costs) is
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known or suspected to be confounded. Figure 1 illustrates
this situation using a directed acyclic graph [15].
Figure 1 shows that BMI is related to healthcare costs,
but a third variable (or variables) influences both BMI and
costs. For example, mental health may be unobserved, but
if individuals with worse mental health are more likely to
have higher BMI and (independently) have higher health-
care costs, the relationship between BMI and costs is
confounded. However, in general, these confounding
variables may be unknown, known but measured with
error, or known but not quantifiable. A simple linear
regression of outcome on exposure would not identify the
causal influence of exposure in the presence
of confounding.
In the next section, we describe how instrumental vari-
able analysis using genetic variants can offer a means of
identifying the causal effect of an exposure (such as obesity
or BMI) on an outcome (such as healthcare costs). We
begin by providing some biological context.
2.2 Genetics and the Basis for Mendelian
Randomization
The human genome is made up of 23 pairs of chromosomes
located in the nucleus of almost every cell in the human
body. Chromosomes are made up of molecules of
deoxyribonucleic acid (DNA), which is constituted (in
part) by nucleotides, themselves comprising nucleobases:
cytosine (C), guanine (G), adenine (A) and thymine
(T) [16].
The region of the chromosome at which a specific
genetic variant in a DNA sequence is located is called
its locus [17]. Each locus in the human genome contains
two alleles; an allele is the particular form of a gene. Single
nucleotide polymorphisms (SNPs) refer to an individual
locus that varies across people in a population. SNPs may
occur during cell division (meiosis). Other forms of vari-
ation are possible, but most commonly researched genetic
variants are SNPs [18].
Individual SNPs can affect different observable traits
such as disease status or health condition. This introduces
the distinction between heredity (the genotype) and the
consequences of that heredity (the phenotype). The phe-
notype can be thought of as an ‘outward’ characteristic or
trait that can be observed and/or measured, while the
genotype is the underlying genetic structure associated
with a specific phenotype [16].
Mendelian randomization is founded on Mendel’s first
and second laws. The first law—the principle of segrega-
tion—states that, during the formation of sex cells (ga-
metes), there is random segregation of alleles from parent
to child. The second law is the independent assortment of
genetic variation at conception. This ‘allocation’ of genetic
variation at the time of conception is approximately ran-
dom, conditional on parental genotype. Genetic variants
that do not affect an outcome of interest other than through
the (phenotypic) risk exposure/health condition with which
they are known to be associated can serve as instruments to
allow researchers to infer the causal effects of health
conditions on outcomes of interest, such as healthcare cost
[19]. Individual genetic variants may therefore be valid
instrumental variables.
In the language of econometrics, the effects of the
endogenous variable (health condition) can be identified by
the exogenous variation induced by the genetic variants.
The genetic variants are assumed to be orthogonal to a
regression error term because of the approximately random
allocation (no confounding or endogeneity) at the time of
conception (no reverse causality) and the absence of
measurement error in the (more precisely measured)
genetic variant instruments. Genome-wide association
studies (GWAS) increasingly provide robust evidence
concerning the association of individual genetic variants
and phenotypes. Thousands of such associations have now
been identified [20], and research continues [21].
An analogy may be drawn with an RCT. In Mendelian
randomization, allocation to ‘treatment’ is indicated by the
genotype, which is known to be associated with the health
condition of interest. Differences in outcomes in people
with different genotypes may then be investigated in a
manner equivalent to an intention-to-treat (ITT) analysis in
an RCT, in which participants are analysed irrespective of
their compliance with the intervention [22].
An important difference between Mendelian random-
ization and RCT analysis is that the genotype of interest
represents a lifelong difference in the health condition or
risk factor concerned, rather than the effects of a short-term
administered intervention. Mendelian randomization can
BMI
Health system 
costs
Mental health 
status
Fig. 1 A relationship between an exposure (body mass index [BMI])
and an outcome (healthcare costs) that is subject to confounding (e.g.
by mental health status)
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potentially estimate the effects of a health condition when
intervention studies would be unethical or impractical, e.g.
the assignation of individuals to alcohol dependence or to
obesity.
2.3 Genetic Variants and the Assumptions
of Instrumental Variables Analysis
Many reviews of Mendelian randomization methodologies
are available [14, 18, 22–25]. This section briefly reviews
three fundamental assumptions of instrument variable (IV)
analysis. These are the same whether the instrument is a
genetic variant or any other (non-genetic) variable.
The three core instrumental variable assumptions are (1)
relevance (the instrument must be associated with the
exposure), (2) independence (the instrument is not associ-
ated with confounders) and (3) exclusion (the instrument
does not directly affect the outcome).1 Further ‘point
identifying’ assumptions, such as monotonicity and ‘no
effect modification’, may also be required and are dis-
cussed elsewhere [18, 24, 26–28].
Figure 2 illustrates a situation where the three IV
assumptions described above are fulfilled by an instru-
mental variable. A Mendelian randomization analysis
could use variants of the FTO gene [29, 30], which are
known to be associated with obesity, as an instrument to
estimate the causal effects of BMI on costs.
In Fig. 2, the instrumental variable (the FTO variant) is
related to the exposure (BMI), indicated by the arrow
pointing from FTO to BMI, and thus the first IV assump-
tion holds. The confounding variable does not influence the
instrument (or vice versa) since there are no arrows
between mental health status and the FTO variant. Thus,
the second assumption is satisfied. Finally, the only arrow
leading from the instrument is to BMI—the instrument
influences costs only via this path and does not otherwise
affect the outcome, as required by the third IV assumption.
2.3.1 The Relevance Assumption
Genetic variants must have a robust association with the
exposure of interest to be valid instrumental variables. This is
known as the relevance assumption [31]. Instrumental vari-
able estimates may be biased when an instrument explains
only a small part of the variation in the exposure [32, 33].
Using genetic variants that have been robustly associatedwith
the exposure in large replicated genome-wide studies can
avoid biases that can arise when choosing genetic variants
whose association with the exposure has been demonstrated
only in a single dataset [34]. Bias can also arise when a
measured exposure is an imperfect proxy for an underlying
exposure. Taylor et al. [34] discuss this possibility with an
example concerning self-reported cigarette consumption as an
imperfect proxy for actual cigarette consumption.
The relevance assumption can be tested by estimating
the association of the variants and the exposure [28]. These
tests could also account for gene–environment interactions.
For example, the relationship between phenotypes and
variants that influence the consumption of food may be
concealed in contexts where little calorific food is available
[14].
2.3.2 Independence Assumption
The independence assumption refers to the independence
of the instrument from all confounders. Intuitively, this can
be understood as the variants being ‘as good as’ randomly
assigned to different individuals.
Population structure can induce associations between
genetic variants and outcomes (e.g. cost) that are not due to
the effect of the exposure of interest (e.g. BMI). This can
occur because of population stratification, by which pop-
ulation subgroups differ in their relationship between the
exposure and outcome. For example, allele frequencies of
FTO are known to vary by ethnic group. If these ethnic
groups also have systematically different healthcare costs
for reasons other than obesity, the independence assump-
tion is violated. This can be accounted for by stratification
of the population according to the subgroup, limiting
analysis to groups with similar ancestral backgrounds or
adjusting for ancestry-informative principal components
[14].
Assortative mating, the preferential mating of like
genotypes (driven by mating of like phenotypes), will also
tend to isolate alleles in certain population subgroups [16].
Assortative mating can violate the independence assump-
tion and introduce bias into Mendelian randomization,
since genetic variants may be confounded by associations
FTO variant
BMI
Health system 
costs
Mental health 
status
Fig. 2 A relationship between an exposure (body mass index [BMI])
and an outcome (costs) that is subject to confounding (by mental
health status) but for which a valid instrumental variable (the FTO
variant) exists
1 The independence and exclusion restrictions are closely related and
are sometimes described as the same assumption, e.g. in Angrist and
Pischke [26].
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with the behavioural or social factors that characterise
these population subgroups.
2.3.3 Exclusion Restriction Assumption
The exclusion restriction is so called because a valid
instrument can be thought of as ‘excluded from’ or ‘ex-
ogenous to’ the causal relationship of interest by virtue of
having no direct effect on the outcome or by being unre-
lated to any other determinant of the outcome [26].
The exclusion restriction can be violated in the presence
of canalization [35], which refers to compensation for the
effects of the variant(s) under investigation. This can cause
estimated effect sizes to be attenuated. Canalization could
reflect changes during gestation or environmental forces
that buffer the consequences to the individual of the health
condition under study.
The interpretation of analysis in this context is similar to
ITT analysis in an RCT, with canalization playing a role
comparable to non-adherence to an intervention. Gene-by-
environment interactions could provide evidence that par-
ticular exposures are affected by canalization. This is
because development will not usually occur in the presence
of a modifiable risk factor; hence, no compensation could
have occurred [36]. However, the availability of datasets to
conduct well-powered studies of these interactions is lim-
ited [37].
Pleiotropy refers to the phenomenon in which a single
locus directly or indirectly affects more than one pheno-
typic trait [14, 22, 38]. Figure 3 provides a simple repre-
sentation [39].
Pleiotropy may violate the exclusion assumption. For
example, assume a hypothetical gene separately influences
both obesity and depression. A Mendelian randomization
analysis using this gene to assess the causal effects of
obesity could be confounded inadvertently by depression if
both traits affect the outcome of interest.
This type of scenario is summarised in Fig. 4 (based on
Lawlor et al. [40]), in which U is a confounding variable
and the pleiotropic effect (PE) creates a pathway for the
variant (Z) to influence the outcome (Y) other than through
the exposure (X).
Note that, even if a variant is pleiotropic, it need not
violate the exclusion restriction, provided that the other
trait does not affect the outcome (i.e. if there is no line from
PE to Y in Fig. 4).
Clear understanding of genetic function is one source of
protection against pleiotropic confounding [37]. Evidence
from multiple IV models that use different combinations of
variants to predict the same causal effect is another
[19, 24, 41]. For example, if many variants (not in linkage
disequilibrium) imply the same causal effect, then pleio-
tropy is unlikely to explain the results. This is because the
same causal effect across different variants could have
been obtained only if the pleiotropy operated in such a way
as to ‘cancel out’ under- and overestimates of effect [37].
Co-inheritance of traits, against Mendel’s second law,
may also violate the exclusion restriction [18, 35]. One
example is linkage disequilibrium, which occurs when
genetic variants tend to be inherited together, so that
variants other than those under study contribute to the trait.
This is illustrated in Fig. 5, which can be compared with
the illustration of pleiotropy in Fig. 4. In Fig. 4, the variant
is connected with a trait that affects the outcome of
interest; in Fig. 5, the variant (denoted G1) is connected
with another variant (denoted G2) that itself affects the
outcome [40]. For example, if FTO tends to be co-inherited
with a variant that predicts a mental health condition,
Gene
Phenotype 1 (e.g. obesity)
Phenotype 2 (e.g. depression)
Fig. 3 Pleiotropy—a gene that affects more than one phenotype
X
Y
U
Z
PE
Fig. 4 A confounded pleiotropic variant. PE pleiotropic effect,
X health condition, U confounding variable(s), Y healthcare cost,
Z instrumental variable
X
Y
U
Z (G1)
G2
Fig. 5 A variant (G1) in linkage disequilibrium with another variant
(G2) that also affects the outcome. X health condition, U confounding
variable(s), Y healthcare cost, Z instrumental variable
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which independently affects healthcare costs, the exclusion
restriction is violated.
The testing of suspected associations and recourse to
evidence on genetic function and known linkages can offer
protection against violations of the exclusion restriction
caused by linkage disequilibrium. For example, ‘maps’ of
the human genome can provide information on linkage
disequilibrium [42]. Linkage disequilibrium need not be
problematic, provided that the second variant (G2 in
Fig. 5) does not affect the outcome (no line from G2 to Y).
The exclusion restriction can be examined indirectly by
establishing whether the proposed genetic variants are
associated with potential confounding factors, or alterna-
tive mediating variables, though one cannot directly test
whether the exclusion restriction is valid. If either or both
of these associations are observed, then the exclusion
restriction is unlikely to hold. However, inference can still
be undertaken even if some instruments are invalid, as
discussed below in Sect 2.5. Pischke and Schwandt [43]
noted that regressing suspected confounders on included
variables can be more informative than regressing the
outcome of interest on suspected confounders if con-
founders are poorly measured.
Genetic variants are generally not related to confounders
that affect observational studies. For example, Davey
Smith et al. [44] found that a variety of behavioural,
socioeconomic and physiological phenotypic variables are
strongly correlated, but genetic variants were not correlated
either with each other or with the phenotypic variables
beyond what would be expected by chance.
However, dynastic effects, in which a genetic trait of a
child is affected by a parental exposure caused by the
parental genotype, can confound variants [45]. For exam-
ple, if a variant carried by a parent causes increased adi-
posity, and this causes a parent to avoid exercise with their
children, then both the variant for adiposity and a beha-
vioural tendency to avoid exercise would be passed on to
the offspring. This could confound the effect of the variant.
Between-sibling (or within-family) Mendelian randomiza-
tion would offer a solution to this.
2.4 Estimating Strategies for Undertaking
Mendelian Randomization Analysis
The Wald estimator, or the ratio method, involves calcu-
lating the ratio of estimated coefficients obtained from a
regression of the outcome on the instrument to the coeffi-
cient obtained from a regression of the exposure on the
instrument. The intuition here is that a unit change in the
outcome for a unit change in the exposure is given by the
ratio of an ‘effect’ of the instrument on the outcome to an
‘effect’ of the instrument on the exposure. The familiar
two-stage least squares (2SLS) estimator will give the same
estimated causal effect as the ratio method when using a
single instrument [28].
Mendelian randomization can be conducted using like-
lihood-based estimators, with Bayesian methods, and semi-
parametric methods such as the generalized method of
moments (GMM) and structural mean models (SMM).
Burgess et al. [28] argued that ‘‘there is no single universal
‘best’ IV estimation method. Instead, the use of different
IV methods provides sensitivity analyses to assess whether
the estimate given by a particular choice of method is
credible.’’
The precision of IV estimates will generally be less than
that of corresponding observational estimators, since the
size of IV standard errors is inversely related to the strength
of the association between instrument and exposure. The
greater consistency of an IV estimator in the presence of
confounding is associated with wider confidence intervals
around estimated effect size.
2.5 Inference with Invalid Instruments
Recent methodological developments offer the possibility
of obtaining unbiased estimates of the causal effect of
exposure, even when some or all of the proposed variants
are invalid.
For example, Bowden et al. [46] proposed a form of
Mendelian randomization analysis that can provide con-
sistent estimates of the treatment effect even if the variants
have pleiotropic effects. Do et al. [47] considered the
detection of causal influences in the presence of pleiotropy
and proposed a two-stage linear regression approach for
summarised data that gives separate estimates for different
risk factors. This type of approach was developed by
Burgess et al. [48, 49], who described a multivariable
approach to Mendelian randomization that allows variants
associated with more than one risk factor to be used in
simultaneous estimation of the causal effect of each risk
individual factor. Kang et al. [50] demonstrated that causal
effects can be identified and estimated using a general-
ization of GMM estimators, even where there is no
knowledge about which specific instruments may be
invalid, provided that less than half of the instruments used
in an analysis are actually invalid.
2.6 Phenotypic Data
Phenotypic data could be drawn from medical records or
other sources such as routinely collected data [51–53].
Phenotypic data can be used as a means of overcoming
some of the challenges of Mendelian randomization, as
an additional source of evidence on which Mendelian
randomization analysis of healthcare costs might be
performed and as an informative body of evidence in its
P. Dixon et al.
own right [54]. Phenome-wide association studies
(PWAS) indicate diseases associated with genetic vari-
ants, whereas GWAS identify variants associated with
disease [53, 55].
Evidence from PWAS can identify associations not
already known from GWAS [56] but can also validate
associations [57] and provide additional evidence on
pleiotropy [57, 58]. The challenges of medical records as a
data source include inconsistencies in coding, coverage and
the diversity of sources and systems [59].
2.7 Instrument Variable Analysis in Mendelian
Randomization
IV analysis in Mendelian randomization needs to reflect
underlying biological relationships and understanding of
gene function. Results need to be interpreted in a manner
that reflects the functional biological context and the
broader population from which data are drawn. Glymour
et al. [60] encouraged ‘aggressive’ evaluation of research
design, encompassing testing of the validity assumptions,
evaluation of biological context and consideration of the
evidence available. Burgess et al. [61] suggested using the
Bradford Hill [62] criteria2 as a basis for judging the
plausibility of the IV assumptions in Mendelian random-
ization analysis.
3 Practical and Methodological Considerations
in Causal Analysis of a Complex Trait
In this section, we illustrate some of the practical and
methodological issues that might affect a Mendelian ran-
domization analysis of the effects of obesity on healthcare
costs.
The prevalence of obesity has increased in recent dec-
ades [11, 63]. It is associated with high healthcare costs
[7], is often comorbid [64], and is known to have a heri-
table component [67]. Furthermore, BMI measurement
error is pervasive [65] and may be substantial [66]. Liter-
ature using Mendelian randomization to examine the
relationship between BMI and health/non-health outcomes
is extensive [24, 68–73].
If obesity is a notable trait on these grounds, it is also a
challenging one. Obesity is a complex trait—many genetic
variants affect BMI [71]. The use of genetic variants might
violate the IV assumptions in a number of ways. We dis-
cuss these in more detail below in Sect 3.1–3.4, outlining
the main methodological issues.
3.1 Weak Instruments
The standard errors of IV estimators are related to the
strength of association between instrument and exposure.
Multiple instruments—such as the many genetic variants
known to be associated with obesity [74]—can improve
statistical power. The intuition for this is that if multiple
instruments are available and orthogonal to regression
errors, then a linear combination will also be orthogonal
[75].
However, multiple weak instruments will bias the IV
estimates toward the observational estimate [18, 76]. Bur-
gess and Thompson [18] suggested this bias can be alle-
viated by using parsimonious models of genetic
association, such as allele scores. Allele scores are
weighted or unweighted variables that combine into a
single variable information from multiple genetic variants,
and this (use of external information) can increase the
power of IV analysis.
All the variants in the score must be valid instruments
for an allele score to meet the IV assumptions; even minor
violations of the exclusion restriction can introduce bias
into approaches using single allele scores. Davies et al. [32]
suggested the use of the continuously updating estimator as
a means of addressing weak instruments. This estimator
can be used in circumstances with multiple risk factors and
many variants in which it would be difficult to create dif-
ferent allele scores for each risk factor.
3.2 Multiple Samples
The data on which estimation is performed need not come
from a single sample [22]. Data on the exposure/outcome
association (such as obesity and healthcare costs) and
variant/exposure relationship (a genetic variant and obe-
sity) could, in principle, be estimated on different samples.
All of the assumptions described concerning validity of
analysis continue to apply, and particular care needs to be
taken to ensure that the populations in each study are
comparable [28]. The absence of individual-level data will
restrict the types of analyses that may be conducted and the
ability to test the IV assumptions may be diminished when
multiple samples are used [77, 78].
3.3 Non-Linearity
Some relationships of interest to health economists, such as
between BMI and healthcare costs, are likely to be non-
2 Briefly, the Bradford Hill criteria (as discussed by Burgess et al.
[61] in relation to Mendelian randomization analysis) are that, for an
exposure to have a causal impact on an outcome, then any association
between the two should (1) be strong, (2) be consistent (i.e. observed
in different places and at different times), (3) be specific, (4) be
temporal, (5) exhibit a biological gradient, (6) be plausible, and (7) be
coherent (i.e. should reflect known facts of the natural history of the
disease and of biology more generally.
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linear [7]. Where exposure–outcome relationships are not
approximately linear, then instrumental variable estimates
using a linear model may not reflect causal effects for large
changes in the exposure [79]. If the exposure–outcome
relationship is both non-linear and non-monotone, even
small changes in values of the exposure will be difficult to
interpret [18].3
If the shape of the exposure–outcome relationship is of
interest, and its association between exposure and genetic
association is the same at different levels of the exposure, then
stratification within different quantiles of the exposure can be
performed to examine the local impacts of the exposure on the
outcome, although stratification should not be directly on the
exposure itself to avoid inducing an association between the
IV and confounders [28, 79]. Silverwood et al. [80] described
a related method for estimating local average treatment
effects for discretized values of the exposure.
3.4 Healthcare Costs as an Outcome in Mendelian
Randomization
Linking healthcare costs to a specific health condition can
be complicated. For example, Lehnert et al. [81] noted that
the physical burden of adiposity itself is not the major
source of economic burden on the individual or on health
systems. Instead, this burden is mostly attributable to
medical conditions that originate from endocrinal and
metabolic changes, such as type 2 diabetes mellitus and
cardiovascular disease.
This gives rise to a conceptual question: should the causal
analysis of the cost consequences of obesity focus on total
healthcare costs or on ‘obesity-related’ costs only? Casting
the net widely to encompass total costs allows for unknown
and unexpected influences on cost causally related to the
variant and exposures of interest to be included in the anal-
ysis. Consider an example of an individual who experiences
a car accident, to which diabetic retinopathy associated with
obesity contributed, and who undergoes an expensive inpa-
tient hospital stay. A focus on ‘obesity-related’ costs that
excluded consideration of this type of emergency admission
could overlook these costs, even though they are caused by
obesity in the scenario described. Both a total cost approach
and an obesity-specific approach could be undertaken if
information on overall resource use and resource use by
diagnostic code is available.
3.5 Data Sources
An ideal data source for the type of analysis proposed in
this paper would contain extensive genotypic information
on as large a group of individuals as possible, linked to
longitudinal medical records and/or routinely collected
administrative claims or reimbursement data. We focus on
the UK Biobank project as an example dataset.
The UK Biobank is a prospective study of approxi-
mately 500,000 participants aged between 40 and 69 years
at recruitment between 2006 and 2010 [82]. Detailed
phenotypic and genotypic data are being collected from
diverse sources, including questionnaires, assays, imaging
and genotyping [82]. As of early 2015, approximately 8500
deaths and 600,000 hospital admissions had also been
recorded via routinely collected data beginning in 1997.
Hospital outpatient episodes from 2003 onwards were
included in 2015, and primary care data will be added in
the future [82].
Part of the UK Biobank’s motivation in recruiting
individuals aged at least 40 years was to ensure a sufficient
number of incident outcomes during the early years of
follow-up. There is likely to be a minor selection effect in
observing the health outcomes of individuals who have
survived to at least 40 years of age.
A more severe issue of selection relates to participation
in the study itself. Participants in the UK Biobank face
lower mortality risks than the general population. This
gives rise to the potential for selection bias (a form of
collider bias) [83], whereby the associations observed
between genetic variants and cost could differ from the
relationship in the general population. This is because the
characteristics that give rise to selection into the study may
affect exposures, and thus exposure–cost relationships. The
incorporation of routine biological sample collection into
population-based databases with wide coverage would help
improve generalisability in other study contexts.
3.6 Textbox 1 Examples of Other Datasets
Studies with wide population coverage include the Age,
Gene/Environment Susceptibility-Reykjavik Study, which
contains linked genetic, phenotypic and medical records
data for a large Icelandic cohort [82]. The Estonian Bio-
bank contains similar information on 5 % (approximately
52,000 individuals) of the Estonian adult population [83].
The UK 100,000 Genome Project plans to sequence
100,000 genomes by 2017. The project has a focus on rare
diseases and on cancer [84, 85]. This will facilitate Men-
delian randomization analysis on these topics, but statisti-
cal power may be limited in some cases. Linkages to
routinely collected data is planned, and issues of general-
isability will again need to be considered.
The eMERGE (electronic MEdical Records and GEno-
mics) network in the USA [84] offers links from over
55,000 participants between DNA repositories and elec-
tronic medical records. Kaiser Permanente is building a
biobank of 500,000 Californian health plan members that3 These considerations apply to IV and non-IV approaches.
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will link medical records and genetic, behavioural and
environmental data [85]. The US Department of Veterans
Affairs is overseeing the Million Veteran Program, which
will create a database of genetic information and medical
care on 1 million volunteers [86].
4 Discussion
There is scepticism that Mendelian randomization can offer
anything to the study of economic outcomes [87] in spite of a
number of studies that have successfully used Mendelian
randomization to address ‘economic’ questions
[24, 41, 50, 88].We have outlined some of the challenges that
would complicate an analysis of the causal effects of BMI/
obesity on healthcare costs. This overview of challenges is
not comprehensive and may vary from experiences involved
in analysing other traits, but it illustrates realistic aspects of
analysis that would likely be encountered.
As with RCTs, the generalizability of a Mendelian
randomization analysis is not secured merely by conduct-
ing a well-designed study. For example, genetic variants
tend to have modest effects on the exposures of interest,
albeit that they influence lifelong exposure and not the
short-term exposures often observed in RCTs, which may
also produce small effect sizes [19].
RCTs and well-designed prospective cohort studies will
continue to be an important source of evidence. However,
there is little or no prospect of obtaining robust causal cost
estimates associated with long-term exposure to many
medical conditions [24]. In circumstances where the con-
sequences of the condition of interest on cost (or some
other outcome) are likely to be material, and considerations
such as measurement error, reverse causality and con-
founding will severely affect observational analyses, then
the case for Mendelian randomization analysis will be
stronger.
5 Conclusion
A comparison is sometimes drawn between the human
genome and a book [89]—the 23 pairs of chromosomes are
chapters, the texts of which are combinations of the
nucleobase ‘letters’: C, G, A and T. Variations between
individuals or chromosomes in single letters of text at
particular parts of these chapters may have consequences
for health. Mendelian randomization is the analysis of this
variation using instrumental variables to make claims about
aetiology and outcomes. We have outlined how Mendelian
randomization could be used to understand the conse-
quences for costs of different health conditions, focusing
on obesity in particular.
Substantial progress has been made in Mendelian ran-
domization-based analyses [23, 37]. This progress has been
driven by new and large data resources, the volume of
evidence emerging from GWAS, and identification and
resolution of methodological challenges.
Mendelian randomization analysis is potentially a
valuable technique for health economists. Contextual rea-
soning, large sample sizes (including multi-sample
designs), a focus on SNPs with material functional conse-
quences, evidence from a variety of sources, information
on biological plausibility, and sensitivity testing could form
elements of a well-designed Mendelian randomization
study. The outputs of these kinds of study could support the
development of more robust evidence for economic eval-
uations and for healthcare priority setting more generally.
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